Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Hum Immunol ; 81(10-11): 634-643, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32771274

RESUMEN

The interaction of tolerogenic CD103+ dendritic cells (DCs) with regulatory T (Tregs) cells modulates immune responses by inducing immune tolerance. Hence, we determined the proportion of these cells in the peripheral blood mononuclear cells (PBMC) of asthmatic patients. We observed lower trends of CD11b-CD103+ DCs and CD86 within CD11b-CD103+ DCs, while increased levels of Foxp3 expressing CD25+/-TNFR2+ cells in asthmatics. There was a positive correlation in the expression of Foxp3 within CD3+CD4+CD25+TNFR2+ Tregs and CD11b-CD103+ as well as the expression of CD86 within HLA-DR+CD11c+CD11b-CD103+ DCs. In conclusion, we suggest that the increased levels of Tregs in blood could continuously suppress the T helper 2 (Th2) cells activation in the circulation which is also supported by the increase of anti-inflammatory cytokines IL-10 and TNF. Overall, functional immunoregulation of the regulatory cells, particularly Tregs, exhibit immune suppression and induce immune tolerance linked with the immune activation by the antigen presenting cells (APC).


Asunto(s)
Antígenos CD/metabolismo , Asma/sangre , Asma/inmunología , Células Dendríticas/inmunología , Cadenas alfa de Integrinas/metabolismo , Receptores Tipo II del Factor de Necrosis Tumoral/metabolismo , Linfocitos T Reguladores/inmunología , Adolescente , Adulto , Anciano , Estudios de Cohortes , Femenino , Humanos , Tolerancia Inmunológica , Interleucina-10/sangre , Activación de Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Células Th2/inmunología , Factores de Necrosis Tumoral/sangre , Adulto Joven
2.
Front Immunol ; 9: 2572, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30473698

RESUMEN

Tumor necrosis factor-alpha (TNF) is a pleiotropic cytokine, which is thought to play a major role in the pathogenesis of inflammatory diseases, including allergy. TNF is produced at the early stage of allergen sensitization, and then continues to promote the inflammation cascade in the effector phase of allergic reactions. Consequently, anti-TNF treatment has been proposed as a potential therapeutic option. However, recent studies reveal anti-intuitive effects of TNF in the activation and proliferative expansion of immunosuppressive Tregs, tolerogenic DCs and MDSCs. This immunosuppressive effect of TNF is mediated by TNFR2, which is preferentially expressed by immunosuppressive cells. These findings redefine the role of TNF in allergic reaction, and suggest that targeting TNF-TNFR2 interaction itself may represent a novel strategy in the treatment of allergy.


Asunto(s)
Hipersensibilidad/inmunología , Inflamación/inmunología , Receptores Tipo II del Factor de Necrosis Tumoral/inmunología , Factor de Necrosis Tumoral alfa/inmunología , Animales , Humanos , Terapia de Inmunosupresión/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...